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ARTICLE OPEN ACCESS CLASS OF EVIDENCE
Randomized, dose-ranging safety trial of
cannabidiol in Dravet syndrome
Orrin Devinsky, MD, AnupD. Patel, MD, Elizabeth A. Thiele, MD,MatthewH.Wong,MD, Richard Appleton,MD,
Cynthia L. Harden,MD, SamGreenwood, PhD, GilmourMorrison, and Kenneth Sommerville,MD,Onbehalf of







To evaluate the safety and preliminary pharmacokinetics of a pharmaceutical formulation of
purified cannabidiol (CBD) in children with Dravet syndrome.
Methods
Patients aged 4–10 years were randomized 4:1 to CBD (5, 10, or 20 mg/kg/d) or placebo taken
twice daily. The double-blind trial comprised 4-week baseline, 3-week treatment (including
titration), 10-day taper, and 4-week follow-up periods. Completers could continue in an open-
label extension. Multiple pharmacokinetic blood samples were taken on the first day of dosing
and at end of treatment for measurement of CBD, its metabolites 6-OH-CBD, 7-OH-CBD, and
7-COOH-CBD, and antiepileptic drugs (AEDs; clobazam and metabolite N-desmethylcloba-
zam [N-CLB], valproate, levetiracetam, topiramate, and stiripentol). Safety assessments were
clinical laboratory tests, physical examinations, vital signs, ECGs, adverse events (AEs), seizure
frequency, and suicidality.
Results
Thirty-four patients were randomized (10, 8, and 9 to the 5, 10, and 20 mg/kg/d CBD groups,
and 7 to placebo); 32 (94%) completed treatment. Exposure to CBD and its metabolites was
dose-proportional (AUC0–t). CBD did not affect concomitant AED levels, apart from an
increase in N-CLB (except in patients taking stiripentol). Themost commonAEs onCBDwere
pyrexia, somnolence, decreased appetite, sedation, vomiting, ataxia, and abnormal behavior. Six
patients taking CBD and valproate developed elevated transaminases; none met criteria for
drug-induced liver injury and all recovered. No other clinically relevant safety signals were
observed.
Conclusions
Exposure to CBD and its metabolites increased proportionally with dose. An interaction with
N-CLB was observed, likely related to CBD inhibition of cytochrome P450 subtype 2C19.
CBD resulted in more AEs than placebo but was generally well-tolerated.
Classification of evidence
This study provides Class I evidence that for children with Dravet syndrome, CBD resulted in
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Data on the efficacy and safety of cannabidiol (CBD) in
various epilepsies are emerging. Randomized controlled trials
have suggested that an orally administered pharmaceutical
formulation of purified CBD as an add-on to existing anti-
epileptic drugs (AEDs) has efficacy in treating convulsive
seizures associated with Dravet syndrome (DS) and drop
seizures associated with Lennox-Gastaut syndrome.1,2 Open-
label trials support these findings and suggest there is efficacy
in other generalized and focal epilepsies, including tuberous
sclerosis complex and febrile infection-related epilepsy
syndrome.3–5 Adverse effects of CBD in patients with
treatment-resistant epilepsy are well-documented in ran-
domized controlled and open-label trials, and most com-
monly include somnolence, diarrhea, and decreased
appetite.1–5
Data are needed on the pharmacokinetics (PK) of CBD in
patients with epilepsy. CBD is metabolized mainly by the
cytochrome P450 (CYP) 2C19 and CYP3A4 isoenzymes,6
which are induced by several AEDs (e.g., carbamazepine,
topiramate, phenytoin) and are inhibited by others (e.g.,
valproate).7 CBD can also inhibit the CYP2C family of iso-
zymes (inhibition constant [Ki] = 1–10 μM) and CYP3A4
(Ki = 1 μM).
6 Thus, drug–drug interactions could exist be-
tween CBD and other AEDs. Several uncontrolled studies
found that the level of the active clobazam metabolite,
N-desmethylclobazam (N-CLB), is increased by CBD,8–10
and 1 study noted interactions with several other AEDs.9
In preparation for a larger randomized controlled trial of
CBD, this trial was conducted to evaluate the dose-ranging
safety, tolerability, and preliminary PK data of add-on CBD
compared with add-on placebo in children with DS.
Methods
The primary research purpose was to evaluate the safety of
multiple doses of CBD compared with placebo (Class I
evidence).
Patients
Patients aged 4–10 years with DS, taking 1 or more AEDs and
experiencing fewer than 4 convulsive seizures during a 4-week
baseline period, were eligible for inclusion. Convulsive seiz-
ures were defined as tonic–clonic, tonic, clonic, and atonic. All
medications and interventions for epilepsy, including keto-
genic diet and vagus nerve stimulation, were stable for 4 weeks
prior to screening and remained unchanged throughout the
trial.
Standard protocol approvals, registrations,
and patient consents
The trial (ClinicalTrials.gov identifier: NCT02091206) was
approved by the institutional review board or independent
ethics committee at each trial site. All patients or parents/legal
representatives provided written informed assent/consent
before trial onset.
Trial design
This multisite, randomized, double-blind, placebo-controlled,
parallel-group trial was conducted at 12 sites in the United
States and United Kingdom between October 2014 and
March 2015. The trial comprised 4-week baseline, 3-week
treatment, 10-day taper, and 4-week safety follow-up periods.
Patients who completed the trial could enter a long-term
open-label extension. An independent data safety monitoring
committee (DSMC) reviewed safety and PK data to de-
termine the target dose and titration regimen for use in future
trials.
Following the 4-week baseline period, patients who satisfied
all eligibility criteria were randomly assigned (through central
randomization via interactive voice/web response system) at
a 4:1 ratio to receive 1 of 3 doses of CBD (5, 10, or 20mg/kg/d)
or placebo of equivalent volume as the treatment doses, added
to their stable AED regimens. CBD oral solution (GW
Pharmaceuticals Ltd., London, UK) contained 25 or 100 mg/
mLCBD; placebo was identical except for the absence of CBD.
Study medication was administered twice daily starting at 2.5
mg/kg/d (or equivalent volume for placebo) and increasing by
2.5–5.0 mg/kg every other day to randomized dose, which
took 3, 7, and 11 days for the 5, 10, and 20 mg/kg/d doses,
respectively. Dose reductions were permitted for adverse
events (AEs).
Protocol amendment
The trial protocol was revised in November 2014 to include
a review of the diagnosis and classification of seizure types in
each patient by an independent panel, appointed by the Ep-
ilepsy Study Consortium, using a standard protocol to con-
firm the diagnosis of DS.1
PK assessments
PK blood samples were taken predose, 2–3 hours postdose,
and 4–6 hours postdose on the first day of dosing and again at
Glossary
6-OH-CBD = 6-hydroxy-cannabidiol; 7-COOH-CBD = 7-carboxy-cannabidiol; 7-OH-CBD = 7-hydroxy-cannabidiol; AE =
adverse event; AED = antiepileptic drug; ALT = alanine aminotransferase; AST = aspartate aminotransferase; AUC = area
under the curve; CBD = cannabidiol; CLB = clobazam; CYP = cytochrome P450; DILI = drug-induced liver injury; DS =
Dravet syndrome; DSMC = data safety monitoring committee; N-CLB = N-desmethylclobazam; PK = pharmacokinetics;
TEAE = treatment-emergent adverse event; ULN = upper limit of normal.
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the same time intervals after 3 weeks of treatment (day 22).
The 3 time points (predose, 2.5 hours, and 5 hours) are the
minimum required to generate an area under the curve
(AUC). Only sparse data were used to derive exposure in-
formation; therefore, no other PK parameters were derived.
Plasma concentrations (measured as total) were analyzed by
ultra-performance liquid chromatography with tandem mass
spectrometry using a validated method for the following:
CBD, 6-hydroxy-cannabidiol (6-OH-CBD), 7-carboxy-can-
nabidiol (7-COOH-CBD), clobazam, N-CLB, valproate,
levetiracetam, topiramate, and stiripentol. The 7-hydroxy-
cannabidiol (7-OH-CBD) metabolite of CBD was also
assessed, but due to analytical issues related to the reference
material batch used, the data could only be considered qual-
itative and are not presented.
Safety assessments
Safety assessments included laboratory assessments (he-
matology, biochemistry, and urinalysis), physical exami-
nations, monitoring of vital signs and ECGs, and
assessments of AEs, seizure frequency, and suicidality
(Columbia-Suicide Severity Rating Scale, performed by
a licensed assessor for the instrument and in children at
least 6 years of age).11
Data analyses
All PK and safety data were summarized using descriptive
statistics; no formal statistical comparisons were planned or
performed. PK exposures were expressed as AUC0–t esti-
mated using a linear trapezoidal linear interpolation method
using WinNonlin v6.3. Dose proportionality was assessed by
regression analysis.
Results
Patient disposition and baseline demographics
A total of 34 patients were randomized: 30 patients at 8 sites
in the United States and 4 patients at 3 sites in the United
Kingdom; 32 patients (94%) completed the treatment period,
and of these, 24 (75%) entered an open-label extension trial
(figure 1). Two patients on CBD were withdrawn during the
treatment period. All 34 randomized patients were included in
the safety analysis set: 10, 8, and 9 patients in the 5, 10, and 20
mg/kg/d CBD groups, respectively, and 7 patients in the
Figure 1 Disposition of patients
There was a delay of ≥23 weeks between treatment completion and when the open-label extension trial was available for enrollment. All pharmacokinetic
analyses were conducted using the safety analysis set. CBD = cannabidiol.
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placebo group. All PK analyses were conducted using the
safety analysis set.
Demographics and baseline characteristics were comparable
between groups (table 1). Seventy-one percent of patients
were white and the mean age was 7.6 years (range 4.0–10.9
years). The most common concomitant AEDs were clobazam
(68%) and valproate (all forms; 65%).
Pharmacokinetics
Mean plasma concentrations of CBD, 6-OH-CBD, and 7-
COOH-CBD over time following single (1.25 mg/kg) or
multiple (5, 10, or 20 mg/kg/d) dosing of CBD are shown in
figure 2A; data are provided in table e-1 (links.lww.com/
WNL/A306). Exposures across the groups on day 1 were
consistent with the common starting dose of 1.25 mg/kg. At
all doses and timepoints, 7-COOH-CBD was the most
abundant circulating metabolite while concentrations of 6-
OH-CBD were consistently <10% those of CBD, based on
AUC0–t. For each analyte, exposure (based on AUC0–t at end
of treatment) increased in a dose-related manner, with no
major deviation from dose proportionality (figure 2B).
Qualitative data generated for the 7-OH-CBDmetabolite also
showed a dose-proportional increase, with plasma exposures
less than that of CBD. At end of treatment, 7-COOH-CBD
levels were 13–17 times those of CBD. Total variability in
AUC0–t for CBD was moderate to high (% coefficient of
variation [%CV] 20%–121%), and was substantially higher
Table 1 Demographics and baseline characteristics
Variable
Cannabidiol dose, mg/kg/d
Placebo (n = 7) Overall (n = 34)5 (n = 10) 10 (n = 8) 20 (n = 9)
Age, y
Mean (SD) 7.2 (1.9) 7.4 (2.1) 8.7 (1.8) 7.0 (0.9) 7.6 (1.8)
Range 4.7–10.9 4.0–10.9 5.4–10.7 6.1–8.8 4.0, 10.9
Sex, n (%)
Female:male 5:5 (50:50) 5:3 (63:38) 6:3 (67:33) 2:5 (29:71) 18:16 (53:47)
Race, n (%)
White 9 (90) 4 (50) 8 (89) 3 (43) 24 (71)
Black/African American 0 3 (38) 0 0 3 (9)
Asian 0 0 1 (11) 0 1 (3)
Other 1 (10) 1 (13) 0 4 (57) 6 (18)
BMI, kg/m2
Mean (SD) 18.9 (4.4) 16.1 (1.5) 16.1 (2.3) 18.7 (4.0) 17.5 (3.4)
Range 14–26 14–19 13–20 14–27 13–27
Concomitant AEDs
Mean (SD) 2.6 (1.1) 2.8 (0.5) 2.8 (0.8) 2.1 (0.9) 2.6 (0.9)
Range 1–4 2–3 1–4 1–3 1–4
AED, n (%)
Clobazam 6 (60) 6 (75) 6 (67) 5 (71) 23 (68)
Valproate (all forms) 7 (70) 5 (63) 8 (89) 2 (29) 22 (65)
Levetiracetam 3 (30) 3 (38) 3 (33) 1 (14) 10 (29)
Topiramate 3 (30) 3 (38) 2 (22) 2 (29) 10 (29)
Stiripentol 1 (10) 2 (25) 2 (22) 2 (29) 7 (21)
Other interventions, n (%)
Ketogenic diet 1 (10) 2 (25) 3 (33) 0 6 (18)
Vagus nerve stimulation 1 (10) 0 1 (11) 0 2 (6)
AED = antiepileptic drug; BMI = body mass index.
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for the metabolites (%CV 57%–1750%) (table e-2). There
was no effect of repeated CBD administration on the 6-OH-
CBD:CBD ratio for AUC0–t, but there was a marked increase
in the 7-COOH-CBD:CBD ratio at end of treatment, sug-
gesting a greater accumulation of this metabolite and that this
was a major route of biotransformation (table e-2).
Following multiple dosing of CBD in patients on regimens
containing clobazam (CLB; n = 17 with end of treatment
data), there was no relevant change in plasma exposure to
CLB; however, there was a notable increase (mean % increase
≥166% in all dose groups) in mean N-CLB concentrations
(range −10% to 526%) (figure 3A) and mean N-CLB:CLB
ratios (range −43% to 664%) (table e-3, links.lww.com/
WNL/A306), with similar mean increases for all 3 CBD doses
(5, 10, 20 mg/kg/d). These increases in N-CLB were not
observed in patients taking stiripentol, a known potent
CYP2C19 inhibitor (n = 4 with end of treatment data) (figure
3B and table e-3). CBD had no effect on systemic exposure to
any other AEDs investigated (valproate, levetiracetam, top-
iramate, or stiripentol), although sample sizes were small
(figure e-1, links.lww.com/WNL/A305). Dedicated drug–
drug interaction studies with valproate and stiripentol, as well
as trials to explore the effects on CYP3A4 and CYP2C19
isozymes as a perpetrator and victim drug, are ongoing.
Safety
Treatment-emergent AEs (TEAEs) were reported in all
groups: CBD 5 mg/kg/d—8/10 patients (80%); 10 mg/kg/
d—5/8 patients (63%); 20 mg/kg/d—7/9 patients (78%);
placebo—6/7 patients (86%). TEAEs experienced by >1
patient overall are provided in table 2. TEAEs occurring in 3
or more patients across the combined CBD groups were
pyrexia, somnolence, decreased appetite, sedation, vomiting,
ataxia, and abnormal behavior. A dose relation was observed
for decreased appetite only. Two patients discontinued be-
cause of AEs: 1 in the 10 mg/kg/d CBD group due to pyrexia
and maculopapular rash, and 1 in the 20 mg/kg/d CBD group
Figure 2 Plasma pharmacokinetics (PK) of cannabidiol (CBD) and metabolites
(A) Arithmetic mean plasma concentrations of CBD, 6-hydroxy-cannabidiol (6-OH-CBD), and 7-carboxy-cannabidiol (7-COOH-CBD) over time at baseline (day
1) and end of treatment (day 22). Note that the day 1 dose was 1.25mg/kg for all 3 treatment groups. (B) Dose linearity for CBD, 6-OH-CBD, and 7-COOH-CBD
exposures (basedon area under the curve [AUC]0–t) at end of treatment (day 22). Qualitative data generated for the 7-OH-CBDmetabolite also showed adose-
proportional increase. R2 values relate to geometric mean fitted regression lines.
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due to elevated transaminases meeting a withdrawal criterion
(alanine aminotransferase [ALT] or aspartate aminotrans-
ferase [AST] >8 × upper limit of normal [ULN]). Trans-
aminases returned to baseline after discontinuation from the
trial.
Six patients (18%) experienced a rash that was reported as
a TEAE: 5 in the CBD and 1 in the placebo group. The rashes
included diffuse maculopapular rash (CBD 10 mg/kg/d),
papular rash (CBD 20 mg/kg/d), localized rash on thigh
(CBD 20 mg/kg/d), viral rash (CBD 5 mg/kg/d), concom-
itant rash and hives (CBD 10 mg/kg/d), and diaper rash
(placebo). All events of rash resolved. There were no cases
showing mucosal involvement and no evidence of Stevens-
Johnson syndrome or toxic epidermal necrolysis.
There were no deaths. Five patients experienced serious
TEAEs (1, 2, and 1 in the 5, 10, and 20mg/kg/d CBD groups,
respectively, and 1 in the placebo group). Serious TEAEs
reported in >1 patient overall were pyrexia (2 in the 10 mg/
kg/d CBD group) and convulsion (1 in the 10 mg/kg/d CBD
group and 1 in the placebo group). Six patients taking CBD
(22%) had elevated ALT or AST >3 × ULN during the trial;
none met the criteria for drug-induced liver injury (DILI) as
there was no elevation of bilirubin >2 × ULN. These ele-
vations were most common in the 20 mg/kg/d group (4/6
patients). All 6 patients were taking concomitant valproate
and 4 of the 6 had concomitant viral/bacterial infections. The
dose of valproate was reduced in 1 patient and elevations in all
6 returned to baseline upon either trial completion (n = 5) or
withdrawal (n = 1). There were no clinically meaningful
observations for clinical laboratory assessments, vital signs, or
ECG results. None of the patients on CBD reported TEAEs
of worsening of seizures or the appearance of new seizure
types during treatment. There were no instances of suicidal
ideation on the Columbia-Suicide Severity Rating Scale after
day 1 through end of study among the patients for whom the
questionnaire was completed.
Discussion
This was a randomized controlled trial of CBD in patients with
DS. Patients had reasonably well-controlled seizures (<4 con-
vulsive seizures during a 4-week baseline) obviating the need
for concomitant AED dose changes and allowing adequate PK
monitoring. This trial showed that exposure to CBD and its
metabolites increased in a dose-proportional manner. Between
the 2 postdose time points assessed, the highest plasma expo-
sures to CBDwere observed during the first time window (2–3
hours). The major circulating metabolite was 7-COOH-CBD
and 6-OH-CBD was a relatively minor circulating metabolite.
There are no published studies on the anticonvulsant activity of
CBD metabolites although such studies are ongoing.
The results show that exposures to CBD and its metabolites
are linearly related to dose over a clinically relevant dose
range, as assessed by AUC at end of treatment. Total vari-
ability in AUC0–t was moderate to high (%CV 20%–121%)
and was higher for the metabolites (%CV 57%–1750%). High
intersubject variability in cannabinoid PK has been noted
previously12 and may reflect various intrinsic and extrinsic
factors that have not been fully evaluated in this trial. These
could include effects of concomitant medications that induce
or inhibit the CYP2C19 and CYP3A4 isoenzymes, genetic
variation in the CYP isoenzymes, variability in food effects, or
differences in tissue distribution.
The combination of all 3 doses of CBD (5, 10, and 20 mg/kg/
d) with clobazam led to a PK interaction with clobazam,
resulting in an elevation of N-CLB plasma exposure in
Figure 3 Percentage change from baseline to end of treatment in plasma clobazam (CLB) and N-desmethylclobazam (N-
CLB) concentrations
(A) By treatment group. Note that 2 patients in the 5 mg/kg/d cannabidiol (CBD) group reduced CLB dose during treatment, but no reason was listed. (B) By
stiripentol use in all patients on CBD. Error bars: SEM.
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patients. This elevation did not occur in the presence of
stiripentol and suggests stiripentol had maximally inhibited
CYP2C19, although additional evidence is needed as the
sample size in the current trial was limited to 4 patients taking
both AEDs. Elevated levels of N-CLB could contribute to
both beneficial (antiseizure)13 and adverse effects (sedation,
fatigue) associated with CBD administration, though addi-
tional sedation was not observed in CLB patients in part B of
this trial.1 There was no obvious effect on the other AEDs
investigated (valproate, topiramate, stiripentol, or levetir-
acetam). These findings are consistent with those of an open-
label trial that found no consistent effect of CBD on levels of
clobazam (n = 22), valproate (n = 18), levetiracetam (n = 12),
felbamate (n = 12), lamotrigine (n = 10), zonisamide (n = 9),
topiramate (n = 5), rufinamide (n = 5), or stiripentol (n =
2).14 Another group reported elevated levels of topiramate,
rufinamide, zonisamide, and eslicarbazepine and decreased
levels of clobazam following CBD administration.9 However,
this trial was an open-label retrospective review with generally
small numbers, timing of AED levels relative to dosing may
have varied, and the extent of the interaction was not repor-
ted; thus, formal interaction studies are required. The
discrepancies may reflect differences in methodologies (e.g.,
consistency of obtaining trough vs random levels at baseline
and post-CBD administration, assay techniques), concomi-
tant AEDs and other medications, demographics (e.g., age,
sex), and other factors.
In the current trial, CBD resulted in more AEs than pla-
cebo. However, it was generally well-tolerated at the 5–20
mg/kg/d dose range and the safety findings were consistent
with the profile seen in open-label studies. Elevated trans-
aminases (ALT or AST) were reported without association
with DILI. In keeping with a previous trial,3 we observed an
increased frequency of elevated transaminases with con-
comitant use of valproate; all elevations subsequently re-
solved, 1 after discontinuing CBD and reducing valproate
dose, and the remaining 5 after trial completion. The 20 mg/
kg/d dose was approved by the DSMC following review of all
safety and PK data, and was employed in the subsequent
randomized controlled trial (GWPCARE1 part B).
CBD and its metabolites showed dose-proportional PK over
a clinically relevant dose range and no interaction with studied
Table 2 Treatment-emergent adverse events experienced by >1 patient overall
Preferred term, n (%)a
Cannabidiol dose, mg/kg/d
Placebo (n = 7) Overall (n = 34)5 (n = 10) 10 (n = 8) 20 (n = 9)
Pyrexia 3 (30) 3 (38) 0 0 6 (18)
Somnolence 2 (20) 3 (38) 0 1 (14) 6 (18)
Decreased appetite 0 1 (13) 4 (44) 0 5 (15)
Sedation 2 (20) 0 2 (22) 0 4 (12)
Vomiting 1 (10) 1 (13) 1 (11) 0 3 (9)
Nasopharyngitis 0 1 (13) 1 (11) 1 (14) 3 (9)
Ataxia 2 (20) 0 1 (11) 0 3 (9)
Gastroenteritis viral 1 (10) 0 1 (11) 1 (14) 3 (9)
Fatigue 0 0 1 (11) 2 (29) 3 (9)
Convulsion 0 1 (13) 0 2 (29) 3 (9)
Abnormal behavior 3 (30) 0 0 0 3 (9)
Gastroenteritis 1 (10) 0 0 2 (29) 3 (9)
Abdominal pain upper 0 0 2 (22) 0 2 (6)
Pneumonia 0 1 (13) 1 (11) 0 2 (6)
Rash 0 1 (13) 1 (11) 0 2 (6)
Viral infection 0 0 1 (11) 1 (14) 2 (6)
Pharyngitis streptococcal 1 (10) 0 0 1 (14) 2 (6)
Psychomotor hyperactivity 1 (10) 0 0 1 (14) 2 (6)
a Patients with >1 occurrence of the same event are counted only once. Adverse events are coded by preferred term using the Medical Dictionary for
Regulatory Activities version 17.0 and are listed in descending order of commonness overall, then by decreasing cannabidiol dose. Only 2 of the 6 events of
rash are included in the table because the other events were reported under different preferred terms with no more than 1 patient each.
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AEDs except for an elevation in N-CLB, that was absent if
concomitant stiripentol was present, possibly reflecting prior
saturation and inhibition of the CYP2C19 isoenzyme. Addi-
tional formal PK trials are needed. All 3 doses of CBD were
generally well-tolerated and the 20 mg/kg/d dose was chosen
by the DSMC as the appropriate dose for further study.
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What is the appropriate dose to administer cannabidiol
(CBD) safely to children with Dravet syndrome (DS)?
Summary answer
CBD is generally well tolerated at all doses tested despite
causing more adverse events (AEs) than placebo treatment.
What is known and what this paper adds
Several randomized controlled trials have suggested thatCBDcan
reduce seizure frequencies in various forms of epilepsy, including
DS. This study provides Class I evidence of the safety of CBD for
children with DS and preliminary pharmacokinetics data.
Participants and setting
This study enrolled 34 patients with DS (mean age, 7.6 years;
range, 4.0–10.9 years). They were taking antiepileptic drugs,
and each experienced fewer than 4 convulsive seizures during
the 4-week baseline period. This study was conducted at 12
US and UK sites between October 2014 and March 2015.
Design, size, and duration
This randomized, double-blind, placebo-controlled trial in-
volved 3-week treatment, 10-day taper, and 4-week safety
follow-up periods. The participants were assigned via central
randomization to the placebo group (n = 7) or to a treatment
group receiving CBD at 5, 10, or 20 mg/kg/d (n = 10, 8, and
9, respectively). These doses were reached after several days
of titration, and dose reductions were permitted following
AEs. CBD or placebo solutions were taken orally. Blood
samples were collected for pharmacokinetics assessments.
Primary outcomes
The primary outcome was participant safety, which was de-
termined with laboratory and clinical assessments and cata-
loguing of AEs and seizure frequencies.
Main results and the role of chance
Two participants withdrew during the treatment period due
to AEs, but they were included in safety assessments. AEs
were reported for 20 (74%) CBD-treated participants and 6
(86%) placebo-treated participants. The most common AEs
among CBD-treated participants included those in the table,
as well as ataxia (11%) and abnormal behaviors (11%). Five
participants (4 CBD-treated and one placebo-treated) expe-
rienced serious AEs, including pyrexia and convulsions. In
terms of pharmacokinetics, exposure to CBD and its metab-
olites was dose-proportional.
Bias, confounding, and other reasons
for caution
This study involved relatively few participants.
Generalizability to other populations
Amaximum baseline seizure frequency was set as an inclusion
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AE
No. (%) of cases
reported in CBD-treated
groups N = 27
No. (%) of cases
reported in
placebo-treated
group N = 7
Pyrexia 6 (22) 0 (0)
Somnolence 5 (19) 1 (14)
Decreased appetite 5 (19) 0 (0)
Sedation 4 (15) 0 (0)
Vomiting 3 (11) 0 (0)
A draft of the short-form article was written by M. Dalefield, a writer with Editage, a division of Cactus Communications. The authors of the
full-length article and the journal editors edited and approved the final version.
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